7 results match your criteria: "University Hospital Centre Nimes[Affiliation]"
Effect of a multimodal analgesia strategy on remifentanil daily consumption in mechanically ventilated adult ICU patients: study protocol for a randomised, placebo-controlled, double-blind, parallel-group clinical trial.
BMJ Open
January 2025
Division of Anesthesia Critical care, Emergency and Pain Medicine, University Hospital Centre Nimes, Nimes, Occitanie, France.
Introduction: Intensive care unit (ICU) patients under mechanical ventilation experience mild-to-severe pain. International guidelines emphasise the importance and benefits of multimodal analgesia to minimise opioid consumption and its side effects. However, no recommendation about drugs or protocol has been formulated.
View Article and Find Full Text PDFProcesses and approaches to perioperative pain management in patients undergoing major lower extremity amputations secondary to vascular disease: a multi-specialty modified Delphi consensus study protocol.
BMJ Open
December 2024
Epidemiology Group, University of Aberdeen Institute of Applied Health Sciences, Aberdeen, UK.
Article Synopsis
- * A modified Delphi methodology will be employed to gather opinions from a diverse group of UK experts through a series of anonymous surveys, aiming for consensus on effective pain management techniques.
- * The study seeks to analyze expert agreement using structured feedback and will only continue if a consensus of at least 75% is reached among participants, although ethical approval was deemed unnecessary.
Efficacy and safety of targeted therapies in VEXAS syndrome: retrospective study from the FRENVEX.
Ann Rheum Dis
September 2024
Médecine Interne, CEREMAIA, Sorbonne Université, Hospital Tenon, Paris, France
Objectives: Vacuoles, E1 enzyme, X-linked, autoinflammatory and somatic (VEXAS) syndrome is an adult-onset autoinflammatory disease associated with somatic ubiquitin-like modifier-activating enzyme 1 (UBA1) mutations. We aimed to evaluate the efficacy and safety of targeted therapies.
Methods: Multicentre retrospective study including patients with genetically proven VEXAS syndrome who had received at least one targeted therapy.
Ureteropelvic junction obstruction with primary lymphoedema associated with variants.
J Med Genet
November 2023
Human Molecular Genetics, de Duve Institute, Brussels, Belgium
Background: Primary lymphoedema (PL) is a chronic, debilitating disease caused by developmental and functional defects of the lymphatic system. It is marked by an accumulation of interstitial fluid, fat and tissue fibrosis. There is no cure.
View Article and Find Full Text PDFAmikacin Liposomal Inhalation Suspension in the Treatment of Lung Infection: A French Observational Experience.
Open Forum Infect Dis
October 2022
Pneumology Department, Hôpital Foch, Suresnes, France.
Background: infections remain difficult to manage in both cystic fibrosis (CF) and non-CF patients and reported clinical outcomes are largely unsatisfactory. Clinical trial data are limited and no approved therapies are currently available for the management of lung diseases. As an alternative, cohort studies may provide insightful information into the management of pulmonary disease.
View Article and Find Full Text PDFPresentation and Real-World Management of Giant Cell Arteritis (Artemis Study).
Front Med (Lausanne)
November 2021
Rheumatology Department, University Hospital La Cavale Blanche, Brest, France.
Few studies of daily practice for patients with giant cell arteritis (GCA) are available. This French study aimed to describe the characteristics and management of GCA in a real-life setting. Cross-sectional, non-interventional, multicenter study of patients ≥50 years old who consulted hospital-based specialists for GCA and were under treatment.
View Article and Find Full Text PDF